SNM Submits Comments to FDA on PET Drugs CGMP Draft Rule and Guidance

December 20, 2005

SNM Submits Comments to FDA on PET Drugs CGMP Draft Rule and Guidance

The Society of Nuclear Medicine (SNM) commented on the draft rule and guidance for current good manufacturing practice (CGMP) for positron emission tomography (PET) drugs (21 CFR Part 212).

The comments were compiled by the SNM CGMP Working Group, charged by President Peter Conti, MD, Ph.D., and led by chairman Henry VanBrocklin, Ph.D. Other CGMP Working Group members include Jeffrey Clanton, M.S., Jeffrey Norenberg, Pharm.D., Joseph Hung, Ph.D., Dennis Swanson, M.S., and Hugh Cannon, SNM Director of Public Affairs.

12/20/2005 SNM Comments on Draft PET Drugs CGMP Rule

12/20/2005 SNM Comments on Draft PET Drugs CGMP Guidance